Key clinical point: Statin exposure reduces the risk for and improves the prognosis of gastric cancer.
Major finding: The statin-exposed vs -nonexposed population showed a significantly reduced incidence (odds ratio [OR] 0.78; P < .001) and improved prognosis (OR 0.78; P = .002) of gastric cancer.
Study details: This was a meta-analysis of 19 studies that analyzed the correlation between statin exposure and the occurrence and progression of gastric cancer.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Lou D et al. Association between statins' exposure with incidence and prognosis of gastric cancer: An updated meta-analysis. Expert Rev Clin Pharmacol. 2022; 1-12 (Aug 15). Doi: 10.1080/17512433.2022.2112178